Review top news and interview highlights from the week ending December 2, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
There was no significant difference in OS and CR rate for patients based on household poverty and neighborhood opportunity.
The director of clinical research at Sierra Eye Associates discussed unmet needs in patients with wet AMD.
Lysogene’s MPS IIIA gene therapy program recently failed its primary endpoint in the phase 2/3 AAVANCE trial.
The FDA has decided not to hold an advisory committee meeting for Roctavian after all.
The chief medical officer of Forge Biologics discussed clinical data presented at ESGCT.